The text discusses the use of FOLFOX4 chemotherapy regimen in non-metastatic colon cancer, showing improved survival rates compared to other treatments. Studies have also shown the benefit of adding oxaliplatin to adjuvant chemotherapy, particularly in stage III MSI patients. However, combinations of irinotecan and 5-FU have not shown efficacy in the adjuvant setting.